Research Progress on the Combination Therapy of EGFR-TKIs and Metformin
in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 874-880, 2023.
Article
en Zh
| WPRIM
| ID: wpr-1010095
Biblioteca responsable:
WPRO
ABSTRACT
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR are effective in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients, but drug resistance is inevitable. With the application and expansion of individualized and combined therapy, more and more studies have shown that combined administration of Metformin effectively solves the problem of acquired drug resistance to EGFR-TKIs in clinical treatment and prolongs the survival of patients with NSCLC. EGFR-TKIs combined with Metformin is expected to be the treatment method of choice for NSCLC patients with EGFR-TKIs resistance. This paper intends to summarize the research progress of EGFR-TKIs combined with Metformin in the treatment of EGFR-TKIs acquired resistance in NSCLC, in order to provide a new idea for the treatment of NSCLC patients with acquired resistance to EGFR-TKIs.
.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Resistencia a Antineoplásicos
/
Inhibidores de Proteínas Quinasas
/
Receptores ErbB
/
Neoplasias Pulmonares
/
Metformina
/
Mutación
Límite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Año:
2023
Tipo del documento:
Article